-
2
-
-
43449108812
-
Economic costs of diabetes in the U.S. in 2007
-
American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008; 31(3):1-20.
-
(2008)
Diabetes Care
, vol.31
, Issue.3
, pp. 1-20
-
-
American Diabetes Association1
-
3
-
-
79956326006
-
Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: Meta-analysis of randomized controlled trials
-
Esposito K, Cozzolino D, Bellastella G et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2011; 13:594-603.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 594-603
-
-
Esposito, K.1
Cozzolino, D.2
Bellastella, G.3
-
4
-
-
79961222810
-
Pharmacology of dipeptidyl peptidase-4 inhibitors, similarities and differences
-
Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors, similarities and differences. Drugs. 2011; 71:1441-67.
-
(2011)
Drugs
, vol.71
, pp. 1441-1467
-
-
Baetta, R.1
Corsini, A.2
-
5
-
-
84866268783
-
Management of hyperglycemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
-
Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35:1364-79.
-
(2012)
Diabetes Care
, vol.35
, pp. 1364-1379
-
-
Inzucchi, S.E.1
Bergenstal, R.M.2
Buse, J.B.3
-
7
-
-
84862645734
-
Alogliptin as an initial therapy in patients with newly diagnosed, drug naive type 2 diabetes: A randomized, control trial
-
Kutoh E, Ukai Y. Alogliptin as an initial therapy in patients with newly diagnosed, drug naive type 2 diabetes: a randomized, control trial. Endocrine. 2012; 41:435-41.
-
(2012)
Endocrine
, vol.41
, pp. 435-441
-
-
Kutoh, E.1
Ukai, Y.2
-
8
-
-
84863436536
-
Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors
-
Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012; 51:501-14
-
(2012)
Clin Pharmacokinet
, vol.51
, pp. 501-514
-
-
Golightly, L.K.1
Drayna, C.C.2
McDermott, M.T.3
-
9
-
-
79952383225
-
Pharmacological and clinical profile of alogliptin benzoate (NESINA)
-
In Japanese
-
Takeuchi K, Fujita T, Hiroi S. [Pharmacological and clinical profile of alogliptin benzoate (NESINA)]. Nihon Yakurigaku Zasshi. 2011; 137:43-50. In Japanese.
-
(2011)
Nihon Yakurigaku Zasshi
, vol.137
, pp. 43-50
-
-
Takeuchi, K.1
Fujita, T.2
Hiroi, S.3
-
10
-
-
77957696165
-
Alogliptin: A review of its use in the management of type 2 diabetes mellitus
-
Scott LJ. Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2010; 70:2051-72.
-
(2010)
Drugs
, vol.70
, pp. 2051-2072
-
-
Scott, L.J.1
-
11
-
-
67651173077
-
Incretin-based therapies for type 2 diabetes mellitus
-
Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol. 2009; 5:262-9.
-
(2009)
Nat Rev Endocrinol
, vol.5
, pp. 262-269
-
-
Lovshin, J.A.1
Drucker, D.J.2
-
12
-
-
58149171060
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control
-
DeFronzo RA, Fleck PR, Wilson CA et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control. Diabetes Care. 2008; 31:2315-7.
-
(2008)
Diabetes Care
, vol.31
, pp. 2315-2317
-
-
DeFronzo, R.A.1
Fleck, P.R.2
Wilson, C.A.3
-
13
-
-
84867136387
-
Natiuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice
-
Rieg T, Gerasimova M, Murray F et al. Natiuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am J Physiol Renal Physiol. 2012; 303:F963-71.
-
(2012)
Am J Physiol Renal Physiol
, vol.303
, pp. F963-F971
-
-
Rieg, T.1
Gerasimova, M.2
Murray, F.3
-
14
-
-
65649116135
-
Alogliptin: A new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
-
Pratley RE. Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2009; 10:503-12.
-
(2009)
Expert Opin Pharmacother
, vol.10
, pp. 503-512
-
-
Pratley, R.E.1
-
15
-
-
73649128872
-
Pharmacokinetics of alogliptin when administered with food, metformin or cimetidine; a two-phase, crossover study in healthy subjects
-
Karim A, Covington P, Christopher R et al. Pharmacokinetics of alogliptin when administered with food, metformin or cimetidine; a two-phase, crossover study in healthy subjects. Int J Clin Pharmacol Ther. 2010; 48:46-58.
-
(2010)
Int J Clin Pharmacol Ther
, vol.48
, pp. 46-58
-
-
Karim, A.1
Covington, P.2
Christopher, R.3
-
16
-
-
41649102998
-
Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl-4 inhibitor alogliptin in male subjects
-
Christopher R, Covington P, Davenport M et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl-4 inhibitor alogliptin in male subjects. Clin Ther. 2008; 30:513-27.
-
(2008)
Clin Ther
, vol.30
, pp. 513-527
-
-
Christopher, R.1
Covington, P.2
Davenport, M.3
-
17
-
-
70549085872
-
Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes
-
Christopher R, Karim A. Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes. Expert Rev Clin Pharmacol. 2009; 2:589-600.
-
(2009)
Expert Rev Clin Pharmacol
, vol.2
, pp. 589-600
-
-
Christopher, R.1
Karim, A.2
-
18
-
-
41649083174
-
Pharmacokinetic, pharmacodynamics, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, controlled, double-blind, placebo-controlled, multiple dose study in adult patients with type 2 diabetes
-
Covington P, Christopher R, Davenport M et al. Pharmacokinetic, pharmacodynamics, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, controlled, double-blind, placebo-controlled, multiple dose study in adult patients with type 2 diabetes. Clin Ther. 2008; 30:499-512.
-
(2008)
Clin Ther
, vol.30
, pp. 499-512
-
-
Covington, P.1
Christopher, R.2
Davenport, M.3
-
19
-
-
67649360705
-
Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin in Japanese healthy male subjects
-
Abstract
-
Hirayama M, Matsuno K, Fujita T et al. Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin in Japanese healthy male subjects. Diabetes. 2008; 57(suppl 1):A155. Abstract.
-
(2008)
Diabetes
, vol.57
, pp. A155
-
-
Hirayama, M.1
Matsuno, K.2
Fujita, T.3
-
20
-
-
67649337808
-
Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment
-
Abstract
-
Karim A, Fleck P, Hetman L et al. Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment. Diabetes. 2008; 57(suppl 1):A160. Abstract.
-
(2008)
Diabetes
, vol.57
, pp. A160
-
-
Karim, A.1
Fleck, P.2
Hetman, L.3
-
21
-
-
77955456705
-
Pharmacokinetics of dipeptidyl peptidase-4 inhibitors
-
Scheen AJ. Pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. 2010; 12:648-58.
-
(2010)
Diabetes Obes Metab
, vol.12
, pp. 648-658
-
-
Scheen, A.J.1
-
22
-
-
70349510604
-
Coadministration of pioglitazone or glyburide and alogliptin: Pharmacokinetic drug interaction assessment in healthy participants
-
Karim A, Laurent A, Munsaka M et al. Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. J Clin Pharmacol. 2009; 49:1210-9.
-
(2009)
J Clin Pharmacol
, vol.49
, pp. 1210-1219
-
-
Karim, A.1
Laurent, A.2
Munsaka, M.3
-
23
-
-
79951699944
-
Initial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes
-
Rosenstock J, Inzucchi SR, Seufert J et al. Initial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes. Diabetes Care. 2010; 33:2406-8.
-
(2010)
Diabetes Care
, vol.33
, pp. 2406-2408
-
-
Rosenstock, J.1
Inzucchi, S.R.2
Seufert, J.3
-
24
-
-
57649225147
-
Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A multicenter, randomized, double-blind, placebo-controlled study
-
Nauck MA, Ellis GC, Fleck PR et al. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicenter, randomized, double-blind, placebo-controlled study. Int J Clin Pract. 2009; 63:46-55.
-
(2009)
Int J Clin Pract
, vol.63
, pp. 46-55
-
-
Nauck, M.A.1
Ellis, G.C.2
Fleck, P.R.3
-
25
-
-
80055037047
-
Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate control on metformin and pioglitazone: A 52-week, randomized, double-blind, active-controlled, parallel-group study
-
Bosi E, Ellis GC, Wilson CA et al. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obes Metab. 2011; 13:1088-96.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 1088-1096
-
-
Bosi, E.1
Ellis, G.C.2
Wilson, C.A.3
-
26
-
-
70450173642
-
Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia
-
Rosenstock J, Rendell MS, Gross JL et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab. 2009; 11:1145-52.
-
(2009)
Diabetes Obes Metab
, vol.11
, pp. 1145-1152
-
-
Rosenstock, J.1
Rendell, M.S.2
Gross, J.L.3
-
27
-
-
84903893337
-
-
Deerfield, IL: Takeda Pharmaceuticals America
-
Nesina (alogliptin) package insert. Deerfield, IL: Takeda Pharmaceuticals America; 2013.
-
(2013)
Nesina (Alogliptin) Package Insert
-
-
-
30
-
-
79959559653
-
Pancreatitis, pancreatic and thyroid cancer with glucagon-like peptide-1-based therapies
-
Elashoff M, Matveyenko AV, Gier B et al. Pancreatitis, pancreatic and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011; 141:150-6.
-
(2011)
Gastroenterology
, vol.141
, pp. 150-156
-
-
Elashoff, M.1
Matveyenko, A.V.2
Gier, B.3
-
31
-
-
84907272031
-
-
Greenwood Village, CO: Truven Health Analytics. Updated periodically
-
Red book database. Greenwood Village, CO: Truven Health Analytics. Updated periodically.
-
Red Book Database
-
-
|